Kornimate/medical-research-clean huggingface dataset:
postoperative pain following restoration with composite resin versus sonic fill

Conditions: Postoperative Pain

Summary: the aim of this study is to assess the postoperative pain following restoration with composite resin versus sonic fill in children with deep carious first permanent molar.

for many years, composite resin restorations have been considered an acceptable treatment choice for anterior applications. recent advances in composite resin mechanical properties and improved adhesive systems have broadened the application of these materials to include the restoration of posterior teeth. however, it is still generally accepted that posterior composite resin restorations have limitations and that there is no ideal material available. a volumetric shrinkage occurs when a composite resin material is cured. the shrinkage is the result of conversion of monomer molecules into a more dense polymer network, which leads to bulk contraction. a new nanohybrid composite activated by sonic energy has been recently introduced as a single-step, bulk-fill restorative material. this system utilizes the patented sonic-activation technology enabling a rapid flow of composite into the cavity for effortless placement and superior adaptation in one single layer, thereby, emphasizes its practical and efficient technique for placing posterior composites. the hand piece, designed by kavo (germany), delivers sonic energy at varying intensities, which is adjusted on the shank from low to high (1 to 5) to control rate of composite extrusion.

Eligibility criteria:
inclusion criteria: * asymptomatic first permanent molar * age of the patient ranging from 6-9 years * normal periodontal status * teeth with no previous restorative treatment * good oral health * absences of pathological mobility exclusion criteria: * adverse medical history * potential behavioral problems * parents refusing participation of their children

Keywords: first permanent molar composite sonic fill resin restoration pediatric dentistry
role of the fibroblast activation protein (fap) as biomarker of fibrotic lung diseases

Conditions: Pulmonary Fibrosis; Lung Fibrosis; Idiopathic Pulmonary Fibrosis; FAP

Summary: to evaluate the effect of an anti-fibrotic treatment initiation on the fibrotic activity as assessed by fapi pet/ct.

to evaluate the use of the fibroblast activation protein (fap) as a biomarker of fibrotic lung disease (idiopathic pulmonary fibrosis (ipf) and non-ipf ilds). the study will include both analysis of fap expression in samples stored in the biobank of the department of pneumology (bal, blood, induced sputum and ebc) (cohort a) and lung fapi uptake on pet/ct scans performed at the department of nuclear medicine: * before and after the initiation of an antifibrotic therapy (ipf or ppf) (cohort b) * before and after the initiation of corticosteroid therapy in case of an acute exacerbation of ild (cohort c) * before and after the initiation of an immunosuppressive drug in the context of non-ipf pulmonary fibrosis (cohort d). * before lung transplantation, surgery or biopsy to correlate with fap expression determined by immunohistochemical analysis (ihc) (cohort e).

Eligibility criteria:
inclusion criteria: * adults patients with a fibrotic lung disease (idiopathic pulmonary fibrosis (ipf) or non-ipf fibrotic ild) as defined according to the 2022 ats/ers/jrs/alat clinical practice guidelines exclusion criteria: * pregnant or nursing patients * patients with another significant medical condition which, in the investigator's opinion, may interfere with the completion of the study. * patients with an active lung neoplasm or any active neoplasm for blood samples

Keywords: pulmonary fibrosis fap
post-marketing safety surveillance of the injection of danshenduofensuanyan a real world study

Conditions: Adverse Drug Reaction

Summary: magnesium lithospermate b, the main constituent of the injection of danshenduofensuanyan (the injection of depsides salts from salvia miltiorrhiza), is the active ingredient of salvia miltiorrhiza. this study record clinical use of the injection of danshenduofensuanyan in the real world, and observe the adverse drug reactions/ adverse drug events during treatment.

as a traditional chinese medicine, the injection of danshenduofensuanyan (the injection of depsides salts from salvia miltiorrhiza) was approved by state food and drug administration of china in may,2005. this cardiovascular drug is one of the few traditional chinese medicine pharmaceuticals where the active ingredients have been identified in the molecular levels. in its 8 years marketing in china, there is no serious adverse drug reactions. in this study, clinical pharmacists in selected hospitals will record the clinical use and the adverse drug reactions/ adverse drug events of this injection. this real world study for the injection of danshenduofensuanyan with 30400 patients will be conducted from june.2012 to may.2014.

Eligibility criteria:
inclusion criteria: * patients who use the injection of danshenduofensuanyan in 30 hospitals in china(including the inpatient and the outpatient(only in some hospitals which can get the information)). exclusion criteria: * none

Keywords: the injection of danshenduofensuanyan magnesium lithospermate b safety real world study
comparison of nonposterior- and posterior-stabilized mobile-bearing total knee arthroplasty

Conditions: Osteoarthritis

Summary: the purpose of this study is to determine if there are any clinical or radiographic differences in non-posterior stabilized rotating mobile bearing design versus a posterior stabilized rotating mobile bearing designs.

out comes measures were to determine 1. whether the knee and function scores and the radiographic results of the knees with a pfc sigma rp knee prosthesis would be better than those with an lcs rp prosthesis. 2. whether the patients with a pfc rp knee prosthesis would have a better range of knee motion than those with an lcs rp prosthesis. 3. whether patient satisfaction and preference would be better in the patients having a pfc sigma rp knee prosthesis than those of patients having an lcs rp knee prosthesis 4. whether complication rate would be less in the knees with a pfc sigma rp knee prosthesis than in the knees with an lcs rp prosthesis.

Eligibility criteria:
inclusion criteria: * end-stage osteoarthritis of the knee joint requiring total knee arthroplasty with bilateral disease exclusion criteria: * inflammatory disease * patient with other lower extremity disease which may affect functional outcome * neurologic disease effecting patients lower extremity * revision surgery * patient not medically cleared for bilateral surgery

Keywords: rotating platform posterior stabilized non-posterior stabilized
vitamin d and hypertensive disorders of pregnancy

Conditions: Hypertensive Disorders of Pregnancy

Summary: the purpose of this study is to further investigate the association between vitamin d deficiency/insufficiency and hypertensive disorders of pregnancy by studying the impact of screening for vitamin d deficiency and supplementation when low levels of vitamin d are detected. screening for vitamin d deficiency (less than 20 ng/ml) and insufficiency (less than 30 ng/ml) may determine the need for additional supplementation, as most prenatal vitamins only contain 400 iu of vitamin d. the rates of hypertensive disorders of pregnancy amongst patients who received supplementation and maintained adequate vitamin d levels will be followed.


Eligibility criteria:
inclusion criteria: * pregnant women * 18-45 years old * receiving care at outpatient ob office of trihealth's women's services comprehensive ob-gyn team with a plan to deliver at bethesda north hospital exclusion criteria: * non-english speaking * unable to provide consent to research study participation * diagnosis of preexisting renal disease * diagnoses of preexisting chronic hypertension * diagnosis of cardiovascular diseases * diagnosis of conditions limiting fat absorption * diagnosis of sarcoidosis

Keywords: vitamin d
surgery with or without lymph node removal in treating older women with stage i breast cancer

Conditions: Breast Cancer

Summary: rationale: surgery to remove axillary lymph nodes may be an effective treatment for women with breast cancer. purpose: randomized phase iii trial to compare the effectiveness of therapy with or without axillary lymph node dissection following quadrantectomy in treating older women with stage i breast cancer that is estrogen receptor positive.

objectives: * compare the efficacy of quadrantectomy with or without axillary lymph node dissection, followed by tamoxifen in terms of local and distant relapse rates and overall survival of patients with stage i, invasive breast cancer. * determine the relationship between biological variables, such as hormone receptor status, cell proliferation, and dna ploidy, and the clinical outcome of the disease in these patients. outline: this is a randomized, multicenter study. patients are stratified by center. patients are randomized to 1 of 2 treatment arms. * arm i: patients undergo quadrantectomy with dissection of level i and ii axillary lymph nodes. * arm ii: patients undergo quadrantectomy without axillary lymph node dissection. patients on both arms receive tamoxifen daily for 5 years. patients are followed every 4 months for 2 years, every 6 months for 2 years, and then annually thereafter. projected accrual: a total of 642 patients will be accrued for this study within 3 years.

Eligibility criteria:
disease characteristics: * histologically proven stage i, invasive breast cancer * hormone receptor status: * estrogen receptor positive * progesterone receptor positive or negative patient characteristics: age: * 65 to 80 sex: * female menopausal status: * postmenopausal performance status: * not specified life expectancy: * not specified hematopoietic: * not specified hepatic: * not specified renal: * not specified other: * no serious disease that would preclude surgery * no other prior or concurrent malignancy except basal cell carcinoma or carcinoma in situ of the cervix prior concurrent therapy: * not specified

Keywords: stage i breast cancer
ceus targeted biopsies compared to mpmri targeted and systematic biopsies for the detection of prostate cancer

Conditions: Prostate Cancer; Prostatic Neoplasms

Summary: the current standard for prostate cancer (pca) detection remains taking 10-12 systematic biopsies of the prostate. this approach leads to overdiagnosis of insignificant pca on the one hand and underdiagnosis and undergrading of significant pca on the other. multiparametric magnetic resonance imaging (mpmri) has seen an increasing uptake in the clinics for biopsy targeting, but the value in biopsy naive patients remains controversial. with contrast enhanced ultrasound (ceus) cancer induced neovascularisation can be visualised with the potential to improve ultrasound imaging for prostate cancer detection and localisation significantly. the past years numerous studies have been performed with ceus, all basing their results on subjective judgement of the investigator. to overcome these difficulties ceus quantification techniques have been used with encouraging first results. these imaging techniques have been proposed to improve the yield of prostate biopsies and possibly replacing systematic biopsies. in this trial mpmri imaging and ceus + quantification are performed before primary biopsy. using a fusion device, targeted biopsies are taken from predefined mri lesions and ceus lesions, together with standard systematic biopsies in the same patients by separate blinded clinicians. the main outcome measure is the per-patient (significant) prostate cancer detection rate for each of the biopsy regimens.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * signed informed consent * referred for mpmri and primary biopsy exclusion criteria: * documented acute prostatitis or urinary tract infections * history of any clinically evidence of cardiac right-to-left shunts * receives treatment that includes dobutamine * severe pulmonary hypertension (pulmonary artery pressure \>90 mmhg) or uncontrolled systemic hypertension or respiratory distress syndrome * has received a biopsy procedure within 30 days before admission into this study * has received a biopsy procedure at the academic medical center within a year before admission into this study * has any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study * is incapable of understanding the language in which the information for the patient is given

Keywords: prostate cancer mri ceus contrast ultrasound fusion targeted biopsy
clinical study of super transplantation in the treatment of severe β-thalassemia

Conditions: Thalassemia Majors (Beta-Thalassemia Major); Haplo-identical Donors

Summary: this is a single-arm, open label, phase 1 study in subjects with beta-thalassemia. this study will evaluate the safety and efficacy of preconditioning-free super-transplantation on beta-thalassemia pediatric patients.

patient screening: 1. two months before transplantation, pediatric patients are evaluated by our center, and the patients meeting the inclusion criteria will be screened into the group. 2. investigators and doctors will give detailed information about the benefits and risks of participating in the study, and the informed consents are further signed. transplant conduction: 1. donor mobilization: hla-fully matched or haplo-identical donors are mobilized subcutaneously for five days with human granulocyte colony-stimulating factor (g-csf) and the peripheral blood mononuclear cells (pbmcs) that contain a certain numbers of cd34+ stem cells and cd3+ lymphocytes will be extracted by blood cell separators. 2. transplant regimen: hydroxycarbamide will be used to reduce the total white blood cells before transplant. however, no traditional transplantation conditioning will be performed, including but not limited to busulfan, fludarabine, cyclophosphamide, atg, and irradiation. splenectomy should be performed if the longitudinal diameter of the spleen exceeds the normal value by 4 cm. 3. cell infusion: pediatric patients will be infused with the pbmcs intravenously at day 0. 4. gvhd prophylaxis: the dosage of immunosuppressants is half of the conventional post-transplantation level, but adjustments to the dosage may be necessary based on specific circumstances. 5. infection management: antibacterial, antifungal medications, and anti-pneumocystis medications need to be administered during the period of granulocytopenia. the preemptive treatment for cytomegalovirus will be performed when the virus serological test is positive.

Eligibility criteria:
inclusion criteria: 1. diagnosis of severe β -thalassemia 2. age between 7-10 years old, male and female; weight \< 40kg 3. the patient has or does not have an hla-compatible or semi-compatible donor, but unconditional transplantation or refusal of blood stem cell transplantation; patients with thalassemia gene therapy without conditions or refusal; 4. there are fully compatible or incompatible hla donors, and the physical examination meets the donor conditions; 5. the patient and family members agree to receive hypertransplant therapy and sign a written informed consent prior to the transplant trial. exclusion criteria: 1. mental patients; 2. participants in other drug clinical trials within the past 1 month; 3. there are no suitable hla-incompatible donors. 4. other researchers decide that it is not suitable to participate in this researcher.
assessment of the symbiotic fermented milk in patients with irritable bowel syndrome

Conditions: Irritable Bowel Syndrome

Summary: this study evaluates the effect of a symbiotic fermented milk on health-related quality of life and irritable bowel syndrome (ibs) symptoms in patients with constipation-predominant ibs.

irritable bowel syndrome (ibs) is one of the most common digestive disorders in the developed world which. it is associated to numerous symptoms, of which the most characteristic are recurrent pain or discomfort in the abdominal region, changes and difficulties related to bowel movements, and bloating. although not dangerous, the disease may significantly impair the patients' quality of life. treatment is symptomatic, but currently not very efficient. the use of probiotics in the treatment of ibs is a promising approach and has been the subject of much research in the last two decades. the purpose of this randomized, placebo-controlled study is to assess changes in health-related quality of life in patients with constipation-predominant ibs after regular consumption of symbiotic fermented milk (containing probiotics and dietary fibres) and to assess its effects on some symptoms, like abdominal pain or discomfort, bloating, and chronic constipation.

Eligibility criteria:
inclusion criteria: * confirmed constipation-predominant irritable bowel syndrome (on the basis of rome iii criteria) (≥ 25 % lumpy or hard stools and ≤ 25 % mushy or watery stools). * meeting rome iii criteria for the determination of irritable bowel syndrome in the last 6 months prior to inclusion and the presence of symptoms such as abdominal pain, bloating and general digestive discomfort at least twice a week in the last 3 months prior to inclusion. * colonoscopy in the last 7 years prior to inclusion with normal results. exclusion criteria: * diarrhoea-predominant irritable bowel syndrome (≥ 25 % mushy or watery stools and ≤ 25 % lumpy or hard stools). * clinical signs of alarm, such as rectorrhagia, fever, recent unexplained weight loss. * organic gastrointestinal diseases, including chronic inflammatory bowel disease and systemic diseases with gastrointestinal difficulties. * severe abdominal pain and the taking of analgesics or antispasmodics for the previous 5 days or more. * having begun treatment with psychotropic medicines or other drugs for the treatment of irritable bowel syndrome within the previous month. * dietary habits that could influence the assessment of the investigational product, such as slimming or a vegetarian diet. * known allergy to ingredient(s) in the investigational product. * known medical or psycho-physical condition that is, in the opinion of the investigator, in conflict with consumption of the investigational product and/or the course of the study. * participation in another clinical study less than one month before inclusion or concurrent participation in another clinical study.
single bolus intravenous ephedrine attenuates reduction of core body temperature in patients undergoing spinal anesthesia for arthroscopic knee and ankle surgery

Conditions: Body Temperature Changes

Summary: a prospective double-blinded randomized controlled study to determine efficacy of ephedrine in preserving core temperature in patients under neuraxial spinal anesthesia for knee and ankle arthroscopic surgery.

to determine the effect of ephedrine on preserving core temperature (tympanic) when given at finishing of local anesthetic administration for spinal neuraxial anesthesia comparing to normal saline (120 minutes period)

Eligibility criteria:
inclusion criteria: * patient undergoing knee or ankle arthroscopic surgery under spinal block at department of orthopaedic ramathibodi hospital * bmi 17-30 kg/m2 * asa physical status 1-3 * age 18-70 * last oral intake more than 6 hours (2 hours for water) * consent form acquired exclusion criteria: * patient who are contraindicated for spinal block * anesthesia level higher than t4 or lower than t10 * tympanic temperature more than 37.5 or less than 35.5 degrees celsius * otitis or other ear infection * patients who receive alpha adrenergic blocker or beta adrenergic blocker * initial blood pressure presenting in operating theater 140 90 mmhg repeat after rest 5 minutes * patient refusal

Keywords: ephedrine core temperature tympanic temperature heat loss spinal anesthesia neuraxial hypothermia shivering
acute and chronic inflammatory disease, lifestyle and treatment response

Conditions: Uveitis

Summary: acute and chronic inflammatory eye diseases are difficult to diagnose and maintain quiescent with therapy. proposed study is aimed to find on the one hand, novel factors for recurrence of the disease or remission of inflammation and evaluation of the impact of lifestyle and known factors on the other. each patient is treated in accordance to the best of medical knowledge and guidelines for each disease. this prospective cohort study will enroll uveitic patients to the steroid only group (sg), combined (steroid and adjuvant drug) group (cg) or bilogic therapy group (btg). at baseline, patient data are recorded using patient-reported outcome measures and clinical assessments (ophthalomology) on disease activity (clinical scales), quality of life, and lifestyle together with registry data on comorbidity and medication. during follow-up evaluation of a successful treatment outcome response will be based on clinical scales and most frequently used primary endpoints; the major outcome of the analyses will be to detect differences in treatment outcome between patients in different treatment group.


Eligibility criteria:
inclusion criteria: * new diagnosis of uni or bilateral uveitis * recurrence of the diagnosed previously uni or bilateral uveitis exclusion criteria: * not mentally able to reply the questionnaire
disclosure of genetic risk for salt sensitivity

Conditions: Salt-sensitive Hypertension

Summary: the global burden of cardiovascular disease (cvd) has decreased over the past 10 years. nevertheless, the disease still kills one in three people. hypertension is one of the leading causes of cardiovascular disease, with salt in the diet being a main contributor. depending on an individual's dna, participants may or may not be salt sensitive. genotyping individuals for variants in a salt sensitivity gene (slc4a5) may identify salt sensitive individuals which may benefit from a personalised dietary advice to reduce salt intake. adherence to such advice can then be assessed which may aid in prevention of hypertension and cvd.

salt sensitivity is a key risk factor for hypertension. however, population decrease in salt intake is less than optimal. research suggests genetics-based personalised nutrition can positively impact health behaviours aiding in the prevention of chronic disease development. however, the effects of communicating such information are unclear. the aims of this study will be to analyse the impact of communicating genetic susceptibility to salt sensitivity on salt intake by assessing dietary salt intake before and after disclosure of genetic risk for hypertension according to the polymorphism in the slc4a5. participants will be normotensive, aged 18-35 years. all individuals will receive genetics-based personalised nutritional information. participants displaying the risk genotype (aa + ac) will be advised to decrease salt intake to less than 4g/d and non-risk will be advised to adhere to government recommendations (6g/d). dietary recall (24hrs) and 24-hour urine collection will be collected at baseline and four-weeks post-intervention to assess salt intake and excretion.

Eligibility criteria:
inclusion criteria: * healthy males and females, aged 18-35 exclusion criteria: * pregnant, cvd events (angina, myocardial infarction, heart failure) or stage 2, hypertension, a bmi ≥30kg/m2, or experiencing mental anguish.